Clinical Study Of Irbesartan In The Treatment Of Hypertension

Objective: To evaluate the efficacy and safety of homemade irbersartan in hypertensive patients.Methods: One hundred and twenty six patients with mild to moderate essential hypertension were randomized into irbesartan(n=64) and benazepril(n=62) groups by double-blind method and treated with irbesartan (150mg/d) and benazepril (lOmg/d) respectively for four weeks. The clinical blood pressure(CBP) and ambulatory blood pressure monitoring(ABP) were performed to compare the efficacy of the two drugs. The influences of irbesartan and benazepril on blood glucose, lipid and function of liver and kidney were also investigated.Results: After four weeks monotherapy, the clinical blood pressure decreased significantly in both irbesartan and benazepril groups(P<0.01). But the heart rates didn't change significantly after the treatment of the two drugs(P>0. 05). No significant difference was found in the extent of the blood pressure reductionbetween the two groups(P>0.05). The markedly effective rates in irbesartan and benazepril groups were 65.63% and 54.84% respectively, and the total effective rates, 81.25% and 75.58%. The effective rates didn't differ significantly between the two groups(P>0. 05). The two drugs both induced significant reduction of ABP(P<0.01) and had no influence on the circadian rhythm of blood pressure. The trough to peak ratio of the two groups was more than 55%. The blood pressure curves both in irbesartan and benazepril groups separated completely before and after treatment. The shape of the curves was just like parallel spirals. The two drugs didn't affect the levels of blood glucose, lipid, electrolyte and the function of kidney and liver (P>0.05) . The incidence rate of adverse effect in irbesartan group was 12. 5%, and benazepril group 22.58%.Conclusion: Both irbesartan and benazepril can decrease blood pressure effectively and safely.